Correction: Chaby et al. Cross-Platform Evaluation of Commercially Targeted and Untargeted Metabolomics Approaches to Optimize the Investigation of Psychiatric Disease. Metabolites 2021, 11, 609
- PMID: 37623909
- PMCID: PMC10456293
- DOI: 10.3390/metabo13080933
Correction: Chaby et al. Cross-Platform Evaluation of Commercially Targeted and Untargeted Metabolomics Approaches to Optimize the Investigation of Psychiatric Disease. Metabolites 2021, 11, 609
Abstract
In the original publication [...].
Figures
Erratum for
-
Cross-Platform Evaluation of Commercially Targeted and Untargeted Metabolomics Approaches to Optimize the Investigation of Psychiatric Disease.Metabolites. 2021 Sep 8;11(9):609. doi: 10.3390/metabo11090609. Metabolites. 2021. PMID: 34564425 Free PMC article.
References
-
- Chaby L.E., Lasseter H.C., Contrepois K., Salek R.M., Turck C.W., Thompson A., Vaughan T., Haas M., Jeromin A. Cross-Platform Evaluation of Commercially Targeted and Untargeted Metabolomics Approaches to Optimize the Investigation of Psychiatric Disease. Metabolites. 2021;11:609. doi: 10.3390/metabo11090609. - DOI - PMC - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
